Also known as: GSBR-1290 · Structure Therapeutics GLP-1
Aleniglipron is an oral, non-peptide small-molecule GLP-1 receptor agonist from Structure Therapeutics (developer code GSBR-1290), in Phase 2b development for obesity. Included here for its direct relevance to peptide-class GLP-1 drugs, the same treatment given to orforglipron.
Aleniglipron activates the GLP-1 receptor as a synthetic small molecule rather than a peptide. In the Phase 2b ACCESS trial (published in Nature Medicine, 2026), once-daily oral dosing escalated over 4 weeks to 45, 90, or 120 mg produced placebo-adjusted body-weight change of −8.2%, −9.8%, and −11.3% respectively at week 36.
Because it is not a peptide substrate for gut proteases, aleniglipron does not require the SNAC-style absorption enhancer that oral peptide GLP-1 drugs like semaglutide need. It is not yet FDA-approved; Phase 3 development status was not confirmed at time of writing.
Aleniglipron binds within the GLP-1 receptor's transmembrane pocket, stabilizing an active, Gs-coupled receptor conformation and triggering the same downstream cAMP/PKA signalling cascade that native GLP-1 and peptide agonists activate — via a different binding mode than the extended extracellular-domain engagement peptide agonists use.
Aleniglipron (developer code GSBR-1290) is a Structure Therapeutics oral, non-peptide small-molecule GLP-1 receptor agonist — included here for its direct relevance to peptide-class GLP-1 drugs it competes with and is frequently compared against, the same treatment given to orforglipron. In the Phase 2b ACCESS trial (Nature Medicine, 2026), 36-week placebo-adjusted body-weight change was −8.2%, −9.8%, and −11.3% for the 45, 90, and 120 mg arms respectively. Gastrointestinal side effects (nausea, constipation, diarrhea) were mild to moderate and declined over time, consistent with the GLP-1 class. Not yet FDA-approved; Phase 3 development status was not confirmed at time of writing.
Like other GLP-1-class weight-management drugs, aleniglipron is being developed for ongoing use rather than cycling.
Phase 2b / investigational — not an approved medicine. Molecular formula, weight, and CAS number are not publicly disclosed.
Ask anything about Aleniglipron — mechanisms, dosing protocols, interactions, or research comparisons.
Semaglutide is an FDA-approved GLP-1 receptor agonist used for type 2 diabetes (Ozempic) and chronic weight management (…
Tirzepatide (Mounjaro/Zepbound) is the first FDA-approved dual GIP/GLP-1 receptor agonist, developed by Eli Lilly. It pr…
AOD-9604 is a modified fragment of human growth hormone (hGH residues 177–191) with an added N-terminal tyrosine residue…
Cagrilintide (AM833) is a long-acting amylin analogue developed by Novo Nordisk. It mimics the satiety and gastric-empty…